Global Toxoid Vaccine Market Research and Forecast, 2022-2028

Description

List of Tables

Global Toxoid Vaccine Market Size, Share & Trends Analysis Report by Disease (Tetanus, Diphtheria, and Pertussis), by Composition (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus and Diphtheria (TD), and Tetanus, Diphtheria, and Pertussis (TDAP)), by Form (Quadrivalent, Pentavalent, and Hexavalent), and by End-User (Hospitals, Clinics (Veterinary), and Government) Forecast Period (2022-2028)

The global toxoid vaccine market is anticipated to grow at a substantial CAGR of 4.5% during the forecast period. Toxoid vaccines use harmful products or toxins developed by the germ that causes a disease. These vaccines create immunity to the parts of the germ, which further divert the immune response to target the toxin instead of the whole germ. The primary factor contributing to the growth of the market includes the rising prevalence of tetanus and diphtheria along with clinical trials of vaccines. According to Clinicaltrials.gov, in 2020, a title published named Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects is under the phase-2clinical trials.

The global toxoid vaccine market is segmented based on disease, composition, form, and end-user. Based on the disease, the market is sub-segmented into tetanus, diphtheria, and pertussis. Based on the composition, the market is sub-segmented into monovalent tetanus toxoid (TT), tetanus and pertussis (DTaP), diphtheria and tetanus (DT), tetanus and diphtheria (TD), and tetanus, diphtheria, and pertussis (TDAP). Based on the form, the toxoid vaccine market is further augmented into quadrivalent, pentavalent, and hexavalent. Further, based on the end-user, the market is sub-segmented into hospitals, clinics (veterinary), and government. Among the composition, the DTaP segment is expected to hold a considerable share in the market across the globe, owing to the rising various government initiatives to reduce and eradicate cases of these diseases. According to the World Health Organization (WHO) reports released in 2021, as of November 2020, five countries in America had reported a total of 56 confirmed cases of diphtheria, with 16 deaths. For instance, in June 2022, the National Health Mission replaced the TT vaccine with the DTaP vaccine in UIP to limit the continuously declining immunity against diphtheria in the population aged 60 years and above.

Geographically, the global toxoid vaccine market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is expected to hold a prominent market share in the global toxoid vaccine market. Owing to the rising incidences of tetanus and diphtheria along with higher cost, coverage, and adoption of vaccines in the region. According to the WHO report published in May 2019, around 56 cases of tetanus and diphtheria were reported in 2019, out of which the laboratory-confirmed 6 cases and 1 death.

The major companies serving the global toxoid vaccine market include AstraZeneca Plc, Astellas Pharma Inc. Bayer, Bharat Biotech, Ceva, Emergent Biosolutions Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Merck & Co. Inc. collaborated with Sanofi SA to launch VAXELIS (DT) in the US. The vaccine was approved by the Food and Drug Administration (FDA)back in 2018.

Research Methodology

The market study of the global toxoid vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Toxoid Vaccine Market Research and Analysis by Disease.

Global Toxoid Vaccine Market Research and Analysis by Composition.

Global Toxoid Vaccine Market Research and Analysis by Form.

Global Toxoid Vaccine Market Research and Analysis by End-User.

The Report Covers

Comprehensive research methodology of the global toxoid vaccine market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global toxoid vaccine market.

Insights about market determinants that are stimulating the global toxoid vaccine market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Product Code: OMR2018254

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Toxoid VaccineMarket
Recovery Scenario of Global Toxoid VaccineMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. ByRegion

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Toxoid VaccineMarket by Disease
- 4.1.1. Tetanus
- 4.1.2. Diphtheria
- 4.1.3. Pertussis
4.2. Global Toxoid VaccineMarket by Composition
- 4.2.1. Monovalent Tetanus Toxoid (TT)
- 4.2.2. Diphtheria, Tetanus, and Pertussis (DTaP)
- 4.2.3. Diphtheria and Tetanus (DT)
- 4.2.4. Tetanus and Diphtheria (TD)
- 4.2.5. Tetanus, Diphtheria, and Pertussis (TDAP)
4.3. Global Toxoid VaccineMarket by Form
- 4.3.1. Quadrivalent
- 4.3.2. Pentavalent
- 4.3.3. Hexavalent
4.4. Global Toxoid Vaccine Market by End-User
- 4.4.1. Hospitals
- 4.4.2. Clinics(Veterinary)
- 4.4.3. Government

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Astrazeneca PLC
6.2. Astellas Pharma Inc.
6.3. BAYER AG
6.4. Bharat Biotech
6.5. CEVA Sante Animale S.A.
6.6. Emergent Biosolutions Inc.
6.7. GlaxoSmithKline PLC
6.8. GRIFOLS S.A.
6.9. Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
6.10. Novartis AG
6.11. Panacea Biotec Ltd.
6.12. Paxvax Inc.
6.13. Pfizer Inc.
6.14. Sanofi Pasteur Inc.
6.15. Sinovac Biotech Ltd.
6.16. The Serum Institute Of India Limited
6.17. Virbac
6.18. Valeant Pharmaceuticals
6.19. Integrated Biotherapeutics
6.20. ZOETIS